Time to clearance of high-risk human papillomavirus infection. At each visit [clinicaltrials_resource:45f68a3e8ecac8b99eb1e1ea7f204da2]
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Time to clearance of high-risk human papillomavirus infection. At each visit [clinicaltrials_resource:45f68a3e8ecac8b99eb1e1ea7f204da2]
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Bio2RDF identifier
45f68a3e8ecac8b99eb1e1ea7f204da2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:45f68a3e8ecac8b99eb1e1ea7f204da2
measure [clinicaltrials_vocabulary:measure]
Time to clearance of high-risk human papillomavirus infection.
time frame [clinicaltrials_vocabulary:time-frame]
At each visit
description
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
identifier
clinicaltrials_resource:45f68a3e8ecac8b99eb1e1ea7f204da2
title
Time to clearance of high-risk human papillomavirus infection. At each visit
@en
type
label
Time to clearance of high-risk ...... 68a3e8ecac8b99eb1e1ea7f204da2]
@en